Abstracts tagged "anti-CCP antibodies"

Abstract Number: 1010 • 2012 ACR/ARHP Annual Meeting
Bone Loss Before Clinical Onset of Rheumatoid Arthritis o Subjects with Anti-Citrullinated Protein Antibodies
Stephanie Finzel¹, Veronika Lang², Arnd Kleyer¹, Juergen Rech³, Bernhard Manger¹, Elizabeth Araujo¹, Axel J. Hueber⁴, Ulrike Harre⁵ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Dept. of Medicine, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Institute for Clinical Immunology, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a major risk factor for rapid disease progression in rheumatoid arthritis (RA). We have recently shown that ACPA directly…
Abstract Number: 2130 • 2012 ACR/ARHP Annual Meeting
Studies of Disease and Therapy-Response Biomarkers in Early Rheumatoid Arthritis Treated with Methotrexate
Aase Haj Hensvold¹, Saedis Saevarsdottir*², Wanyiang Li*³, Vivianne Malmström⁴, Guy Cavet⁵, Lars Klareskog⁶ and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Crescendo Bioscience Inc. 341 Oyster Point Blvd South San Francisco, CA 94080, San Francisco, CA, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
*equally contributed Background/Purpose: To identify disease and therapy response serum biomarkers in early untreated RA patients started on methotrexate as the only DMARD. Methods: 186…
Abstract Number: 977 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Novel Citrullination Target in Rheumatoid Arthritis That Enhances Diagnostic Utility in Anti-CCP Negative Patients
Walter P. Maksymowych¹, Vivian P. Bykerk², Désirée van der Heijde³, R. Landewe⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: 14-3-3 eta is normally an intracellular protein and only in the disease state is it released into the extracellular space. We have previously presented…
Abstract Number: 2114 • 2012 ACR/ARHP Annual Meeting
Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB1 Shared Epitope and Anti-CCP
Jose Felix Restrepo¹, Inmaculada del Rincon¹, Roy W. Haas², Daniel F. Battafarano³ and Agustin Escalante², ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX
Background/Purpose: The HLA-DRB1 shared epitope (SE) and antibodies to cyclic citrullinated peptides (anti-CCP) are important to the susceptibility to rheumatoid arthritis (RA), and are thought…
Abstract Number: 973 • 2012 ACR/ARHP Annual Meeting
New Genetic Risk Loci for the Radiographic Severity of Rheumatoid Arthritis
Diederik P.C. de Rooy¹, Sacha Zhernakova¹, Roula Tsonaka², Fina Kurreeman³, René E.M. Toes¹, Tom W. J. Huizinga⁴, Jeanine Houwing-Duistermaat⁵, Peter K. Gregersen⁶ and Annette H.M. van der Helm-van Mil¹, ¹Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Medical Statistics, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Statistics, Statistics, Leiden University Medical Center, Leiden, Netherlands, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: The severity of joint destruction is highly variable between Rheumatoid Arthritis (RA) patients; approximately 54% of this variance is explained by genetic factors. Many…
Abstract Number: 2116 • 2012 ACR/ARHP Annual Meeting
The Associations of HLA-DR Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis
Mehret Birru Talabi¹, Rachel Mackey², Larry W. Moreland³, Jan Dorman⁴, Kevin D. Deane⁵, Jeremy Sokolove⁶, V. Michael Holers⁷, William H. Robinson⁸, Brian Wallitt⁹ and Lewis Kuller¹⁰, ¹Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴School of Nursing, University of Pittsburgh School of Nursing, Pittsburgh, PA, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Washington Hospital Center, Baltimore, MD, ¹⁰Epidemiology, University of Pittsburgh, Pittsburgh, PA
Title: The Associations of HLA-DRβ1 Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid ArthritisBackground/Purpose: This study…
Abstract Number: 436 • 2012 ACR/ARHP Annual Meeting
Synthetic Anti-CCP Antibody Aggravated Severity of Animal Arthritis and Captured Citrullinated Antigen in the Serum of Patients with Rheumatoid Arthritis
Youngkyun Kim¹, Su-Jin Moon², Hyoju Yi² and Ji Hyeon Ju³, ¹1Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, ²Rheumatology, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Rheumatology, College of Medicine, The Catholic University of Korea & Stanford University, Seoul & Palo Alto, CA
Background/Purpose: Auto-antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the prognosis and diagnosis of rheumatoid arthritis (RA), and have been implicated in…
Abstract Number: 2120 • 2012 ACR/ARHP Annual Meeting
Predictive Value of Anti-CCP Positivity On Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results From the Swedish EIRA Study
Saedis Saevarsdottir¹, Marie Holmqvist², Johan Askling³, Lars Alfredsson⁴ and Lars Klareskog⁵, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Does anti-CCP-positivity predict disease course and response to therapy in early rheumatoid arthritis (RA)? Methods: We retrieved clinical follow-up data for patients entering the…
Abstract Number: 439 • 2012 ACR/ARHP Annual Meeting
Interaction of Antibodies Against Citrullinated Peptides with HLA Shared Epitope, PTPN22 1858T Variant, and Smoking in Individuals Prior to and After the Development of Rheumatoid Arthritis
Heidi Kokkonen¹, Mikael Brink², Monika Hansson³, Linda Mathsson⁴, Ewa Lassen⁵, Per Johan Jakobsson⁶, Rikard Holmdahl⁷, Johan Rönnelid⁴, Lars Klareskog⁸ and Solbritt M. Rantapaa-Dahlqvist⁹, ¹Rheumatology, Umeå University, Umea, Sweden, ²Umea University, Umea, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁵Transfusional Medicin, Umeå University, Umeå, Sweden, ⁶Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁹Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: The presence of antibodies against cyclic citrullinated peptides (ACPA) has been demonstrated to precede the development of rheumatoid arthritis (RA) by several years. The…
Abstract Number: 1769 • 2012 ACR/ARHP Annual Meeting
Affinity Purification and Characterisation of Anti-CCP Antibodies From Plasma and Synovial Fluids of Patients with Rheumatoid Arthritis
Elena Ossipova¹, Catia Cerqueira², Evan Reed², Nastya Kharlamova², Lena Israelsson², Rikard Holmdahl³, Anca Catrina², Vivianne Malmström², Yngve Sommarin⁴, Lars Klareskog², Per Johan Jakobsson² and Karin Lundberg², ¹Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁴Euro-Diagnostica AB, Malmö, Sweden
Background/Purpose: Autoimmunity in rheumatoid arthritis (RA) is characterized by autoantibodies to citrullinated proteins/peptides (ACPA). These antibodies (present in 60-70% of patients) antedate clinical onset and…
Abstract Number: 412 • 2012 ACR/ARHP Annual Meeting
Single Nucleotide Polymorphisms within the HLA-DRB1 Gene in Relation to Antibodies Against Citrullinated Peptides in Individuals Prior to the Development of Rheumatoid Arthritis
Lisbeth Arlestig¹, Mikael Brink², Monika Hansson³, Per Johan Jakobsson⁴, Rikard Holmdahl⁵, Linda Mathsson⁶, Johan Ronnelid⁶, Lars Klareskog⁷ and Solbritt M. Rantapaa-Dahlqvist⁸, ¹Rheumatology, Umeå University, Umea, Sweden, ²Umea University, Umea, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁶Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁷Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁸Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: Multiplex analysis has demonstrated the presence of several antibodies against cyclic citrullinated peptides (ACPA) preceding the development of rheumatoid arthritis (RA) by several years.…
Abstract Number: 1770 • 2012 ACR/ARHP Annual Meeting
Recognition of Citrullinated and Carbamylated Proteins by Human Antibodies: Specificity, Cross-Reactivity and the “AMC-Senshu” Method
Jing Shi¹, George Janssen², Peter van Veelen², Janwouter Drijfhout², Antony Cerami³, Tom Huizinga⁴, Leendert A. Trouw⁵ and René E.M. Toes⁴, ¹Rheumatology, LUMC, Leiden, Netherlands, ²Immunohematology and Bloodbank, LUMC, Leiden, Netherlands, ³Nephrology, LUMC, Leiden, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play an important role in the diagnosis and prognosis of Rheumatoid Arthritis (RA). The Anti-Modified Citrulline (AMC) (‘Senshu’) method is…
Abstract Number: 394 • 2012 ACR/ARHP Annual Meeting
Remission After One Year in ACPA Positive and ACPA Negative Patients with Early Arthritis
K.V.C. Wevers-de Boer¹, L. Heimans¹, K. Visser¹, A.A. Schouffoer², T.H.E. Molenaar³, J.B. Harbers⁴, C. Bijkerk⁵, I. Speyer⁶, M. de Buck⁷, P.B. de Sonnaville⁸, B.A. Grillet⁹, Tom Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Haga Hospital, The Hague, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Franciscus Hospital, Roosendaal, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Bronovo Hospital, Den Haag, Netherlands, ⁷MCH, The Hague, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To evaluate possible differences in clinical response after one year of remission steered treatment in Anti Citrullinated Protein Antibody (ACPA) positive and negative RA…
Abstract Number: 1771 • 2012 ACR/ARHP Annual Meeting
Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis
Jing Shi¹, Lotte van de Stadt², Nivine Levarht³, T.W.J. Huizinga⁴, R. E. M. Toes⁴, Leendert A. Trouw⁵ and Dirkjan van Schaardenburg², ¹Rheumatology, LUMC, Leiden, Netherlands, ²Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Recently, we discovered a new autoantibody system in rheumatoid arthritis (RA): anti carbamylated protein antibodies (anti-CarP). These antibodies have additional prognostic value in predicting…
Abstract Number: 177 • 2012 ACR/ARHP Annual Meeting
Antibodies to Citrullinated Peptides in Tuberculosis
Isabella Lima¹, Rodrigo Oliveira², Ajax Atta², Samyra Marchi³, Lúcio Barbosa³, Eliana Reis³, Mitermayer G. Reis³ and Mittermayer Santiago⁴, ¹Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil, ²Universidade Federal da Bahia, Salvador, Brazil, ³Fundação Oswaldo Cruz, Salvador, Brazil, ⁴Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetric polyarthritis, rheumatoid factor positivity (RF) in the majority of patients, and bone erosions shown…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].